Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PETHEMA Foundation
It is a clinical study multicenter, prospective, open label trial, uncontrolled and nonrandomized
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with acute lymphoblastic leukemia or very aggressive Non-Hodgkin-Lymphoma (Burkitt/Burkitt-like) and CNS relapse.
CNS involvement must be demonstrated by:
A positive ventricular or lumbar CSF cytology defined as CSF cell counts \> 5/µl (19/3 cells), obtained within 10 days prior to inclusion OR
Characteristic signs and symptoms of neoplastic meningitis PLUS an MRI or CT scan indicating the presence of meningeal involvement. Patients with combined relapse in CNS and other locations may be included in case that systemic therapy with CNS active drugs (HDMTX;HDAC, Thiotepa) can be postponed for at least 2 weeks.
Karnofsky \>60%
Age \>18 years old
Recovery from grade III/IV toxicities attributable to prior treatment with the exception of hematotoxicity.
No severe heart, lung, liver or kidney dysfunction.
The patient or guardian must be competent to provide informed consent and must provide written informed consent prior to the initiation of study procedures
You may not be if
Failure (as defined by no clearance of the CSF) to \> 1 dose of prior intrathecal MTX or cytarabine or triple (MTX, ARAC, dexamethasone) therapy
History of previous severe neurotoxicity (grade III-IV) attributed to intrathecal therapy or systemic high-dose therapy with methotrexate or cytarabine (vincristine induced peripheral neuropathy is accepted)
Prior CNS relapse \< 1 month before
uncontrolled infection
The patient must not be pregnant or breast feeding. If the patient is a female of child-bearing potential she must have a negative (urine or serum) pregnancy test and be using effective methods to prevent pregnancy
Clareo Health | Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma
